Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?

Area of Science:

• Immunology
• Rheumatology
• Clinical Diagnostics

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by unpredictable flares.
• Predictive biomarkers for SLE flares are crucial for timely intervention and improved patient outcomes.
• Conflicting literature exists regarding the utility of various autoantibody and complement tests in flare prediction.

Purpose of the Study:

• To assess the diagnostic accuracy (sensitivity, specificity, likelihood ratios) of anti-dsDNA, C3, C4, and Clq binding tests for predicting SLE flares.
• To reconcile discrepancies in previous research on these predictive markers.
• To evaluate the clinical utility of these tests in routine SLE management.

Main Methods:

• A cohort study involving 202 SLE patients was conducted.
• Test results preceding 83 documented flares were analyzed.
• Flares were defined by a significant increase in a modified SLE Disease Activity Index.

Main Results:

• All four tested markers demonstrated low sensitivity (around 50%) and specificity (<75%).
• Anti-dsDNA, C4, and Clq binding tests showed minimal clinical value (likelihood ratios near 1.0).
• C3 testing approached minimal clinical significance, while frequent anti-dsDNA monitoring (every 4-6 weeks) showed potential for flare prediction.

Conclusions:

• Current routine testing with anti-dsDNA, C3, C4, or Clq binding offers limited support for predicting SLE flares.
• Further longitudinal studies focusing on monthly anti-dsDNA monitoring are recommended to establish its predictive role.
• The frequency of testing, rather than the test itself, may be a critical factor in predicting SLE flares.